Sramana Mitra: If you have the stomach and the resilience to stick it out, it gives you the ammunition and ability to gather up a lot of competitive advantage. It’s not easy to build up that kind of competitive advantage in a short order. It’s just a matter of time. If you can survive those
Sramana Mitra: In that revenue model, what does an average deal size look like? Brian Loew: I’ll answer that but also, the other part of research that has actually become larger than that is the market research side of it where pharmaceutical companies want to know about patient perspectives on things. Typically, a pharma will
Sramana Mitra: Social media hasn’t quite taken off yet. 2004 was the beginning of Facebook. Brian Loew: That’s right. You didn’t have vertical social networks. You had message boards. There were some message boards, as you remember, that were good. We thought that there was some opportunity here. I got some friends with web background
Sramana Mitra: What kind of revenue level did you get to with that company? Brian Loew: Somewhere between $15 million to $20 million. We sold that in 2000. One of my Board members was the former President of the Washington Post. I was exhausted after that. He said, “Why don’t you go to the Washington
Sramana Mitra: The story that you described from 1995 to 2008 is not Perigen? Emily Hamilton: Correct. Perigen acquired all of the assets of that company. Sramana Mitra: Who’s Perigen? Matthew Sappern: Perigen is actually the combination of a company called E&C Medical, which was based in Tel Aviv that was trying to do pretty
Sramana Mitra: How many hospitals, for instance, were you able to sell your product to in that early phase right after getting the prototype? Emily Hamilton: Almost all of the hospitals in Montreal. We have two medical schools here. I had colleagues in many of the hospitals who were former students or colleagues for many
Sramana Mitra: When you talk about timing, what year are we talking about? Emily Hamilton: Back in mid-1990s. Sramana Mitra: So you got a bunch of grants to get this thing off the ground. Emily Hamilton: It wasn’t exactly a grant in the traditional sense. This was money which was intended to foster research, which
Sunny Singh: Edifecs has become a business applications company providing business applications for these transformative things happening in healthcare. We have a lot of runway both in the US and international in servicing healthcare. From $100 million, our expectation is to become a $200 million company by 2017. Going back to the point where I